Dorzolamide HCL

Dorzolamide HCL USP / EP / BP / IP / EP

  • Product Name : Dorzolamide HCL
  • CAS : 130693-82-2
  • Molecular Formula : C10H17ClN2O4S3
  • Molecular Weight : 360.9 g/mol
  • Pharmaceutical Grade : USP / EP / BP / IP / EP
  • Therapeutic Category : Antiglaucoma agent

Global Calcium is one of the leading manufacturers and exporters of Dorzolamide HCL CAS no. 130693-82-2, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.

As manufacturer of Dorzolamide HCL we hereby state the following facts about the drug:

Dorzolamide (dorzolamide hydrochloride) is a topical carbonic anhydrase (CA) inhibitor used to lower intraocular pressure (IOP) by reducing aqueous humour formation. It is formulated as a 2% eye drop for use in the management of glaucoma and ocular hypertension.

It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.

Carbonic anhydrase (CA) is a ubiquitous enzyme that catalyses the reversible hydration of carbon dioxide to bicarbonate ions and dehydration of carbonic acid. In the ocular ciliary processes, the local production of bicarbonate by CAs promotes sodium and fluid transport.

Dorzolamide is a highly specific CA-II inhibitor, where it displays a 4000-fold higher affinity for carbonic anhydrase enzyme. The inhibition of CA in the ciliary process disrupts the formation of bicarbonate ions and reduces sodium and fluid transport, which leads to decreased aqueous humour secretion and reduced intraocular pressure.

When administered 3 times daily, dorzolamide is effective in lowering IOP in patients with open-angle glaucoma or ocular hypertension. Mean IOP was reduced by approximately 4 to 6 mm Hg at peak (2 hours post-dose) and 3 to 4.5 mm Hg at trough (8 hours post-dose) as per the data projected in some of the clinical trials.

Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market